Oncolyze Announces FDA Orphan Drug Designation for OM-301 for the Treatment of Acute Myeloid Leukemia

By
Justin.choi
-
0
14
Oncolyze, Inc, announced that the US FDA has granted the company orphan drug designation for its pipeline compound OM-301 for the treatment of acute myeloid leukemia. OM-301 is currently in pre-clinical development for AML and other cancers.
[Oncolyze, Inc. (GlobeNewswire, Inc.)]

Sorry, but the selected Zotpress account can't be found.

Press Release